Doctors Note Logo

Published on: 8/18/2026

Why Skeletons Soften in Adults: HPP Reality & Next Steps

Adult bones can soften when a genetic shortage of the enzyme alkaline phosphatase disrupts mineralization, a condition called hypophosphatasia (HPP). Because mineral never fully deposits into the bone matrix, adults may develop osteomalacia with aching thighs or hips, stress fractures in the feet, early tooth loss, joint pain from calcium crystal deposits, and fatigue that gets dismissed as aging. Blood work often shows low alkaline phosphatase alongside elevated vitamin B6 or urinary phosphoethanolamine, and genetic testing of the ALPL gene can confirm it. Standard osteoporosis drugs such as bisphosphonates may worsen HPP, so an accurate diagnosis changes treatment entirely, with enzyme replacement therapy available for some patients. Several important factors affect how HPP presents and is managed, so review the complete details below before drawing conclusions.

If you're worried about unexplained bone pain, recurring fractures, or dental problems, a free, instant symptom check can help you organize your symptoms and understand which specialists and tests may be most relevant to your situation.

Last reviewed for medical accuracy: 08/18/2026

answer background

Explanation

Why Skeletons Soften in Adults: HPP Reality & Next Steps

Bones give our body structure, protect organs, and enable movement. When our skeleton is healthy, bones stay strong and rigid. However, in some adults, bones can soften—a condition often linked to hypophosphatasia (HPP disease). This guide explains why bones soften in adults with HPP, what to watch for, and how to move forward.

What Is Hypophosphatasia (HPP Disease)?

Hypophosphatasia (HPP) is a rare genetic disorder affecting an enzyme called alkaline phosphatase (ALP). This enzyme plays a key role in bone mineralization—the process of laying down calcium and phosphate to harden bone. When ALP activity is low, minerals don’t bind properly, and bones remain soft or become weak.

Key points about HPP disease:

  • It’s inherited in autosomal recessive or autosomal dominant patterns.
  • Severity ranges from a life-threatening form in infancy to milder adult-onset cases.
  • Adult-onset HPP often presents with bone pain, fractures, and dental issues.

Why Do Skeletons Soften in Adults with HPP?

In adult HPP, reduced ALP activity leads to:

  • Impaired Mineralization
    Bone-building cells can’t deposit calcium and phosphate effectively.
  • Accumulation of Substrates
    Molecules like inorganic pyrophosphate build up and block mineralization.
  • Bone Fragility
    Over time, bones become less dense, more pliable, and fracture easily.

Other factors that may contribute to bone softening in adults:

  • Hormonal changes (e.g., low vitamin D or parathyroid hormone imbalances)
  • Nutritional deficiencies (calcium, phosphate)
  • Coexisting conditions (thyroid disease, kidney dysfunction)
  • Certain medications (long-term steroids)

Common Symptoms in Adult-Onset HPP

Adults with HPP can experience a variety of signs. Not everyone will have every symptom, and severity varies.

Typical features include:

  • Bone pain in legs, hips, back
  • Recurrent fractures or stress fractures
  • Early loss of teeth (especially baby teeth)
  • Muscle weakness and fatigue
  • Joint pain and stiffness
  • Difficulty walking or frequent falls

Less common or supportive signs:

  • Low serum alkaline phosphatase (ALP) levels on blood tests
  • Elevated levels of phosphoethanolamine or pyridoxal 5′-phosphate (vitamin B6)
  • History of childhood rickets or osteomalacia

Diagnosis: How HPP Is Confirmed

Diagnosing HPP disease involves a combination of clinical evaluation, lab tests, imaging, and sometimes genetic studies.

  1. Clinical Evaluation

    • Detailed personal and family history (fractures, dental loss, rickets)
    • Physical exam focusing on bone tenderness or deformities
  2. Laboratory Tests

    • Serum ALP: consistently low values suggest HPP
    • Plasma pyridoxal 5′-phosphate: often elevated due to reduced ALP breakdown
    • Urine phosphoethanolamine: may be high in HPP
  3. Imaging

    • X-rays: reveal bone thinning, pseudofractures, or Looser zones
    • Bone density scan (DEXA): measures overall bone mass
  4. Genetic Testing

    • Confirms mutations in the ALPL gene
    • Helps predict severity and guide family counseling

Treatment Options

There’s no one-size-fits-all cure for HPP, but several strategies can help manage symptoms and strengthen bones.

1. Enzyme Replacement Therapy (ERT)

  • Asfotase alfa: the first approved ERT for HPP
  • Replaces deficient ALP to improve mineralization
  • Administered by injection several times a week
  • Requires monitoring for side effects (injection site reactions, calcium imbalances)

2. Nutritional Support

  • Adequate intake of calcium and vitamin D (under medical supervision)
  • Balanced diet rich in bone-supportive nutrients: magnesium, phosphorus, vitamin K

3. Pain Management

  • Over-the-counter pain relievers (acetaminophen)
  • Low-dose nonsteroidal anti-inflammatory drugs (NSAIDs) if tolerated
  • Physical therapy to strengthen muscles and improve balance

4. Dental Care

  • Early evaluation by a dentist familiar with HPP
  • Customized oral hygiene plans to prevent tooth loss
  • Possible use of dental implants or prosthetics

5. Lifestyle Modifications

  • Low-impact exercises (swimming, cycling, walking)
  • Fall prevention strategies at home (non-slip mats, handrails)
  • Avoidance of activities that risk repeated stress fractures

Monitoring and Follow-Up

Regular check-ups are essential to track progress and adjust treatment:

  • Blood tests every 3–6 months (ALP, calcium, vitamin D)
  • Periodic bone density scans
  • Dental exams at least once a year
  • Assessment of physical function and pain levels

Next Steps: What You Can Do Now

  1. Recognize Symptoms Early
    If you have unexplained bone pain, frequent fractures, or dental issues, consider HPP as a possibility.

  2. Get a Professional Opinion
    Speak to a specialist in metabolic bone diseases or an endocrinologist.

  3. Do an Online Symptom Check
    For a quick, doctor-approved overview of your symptoms, you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker.

  4. Arrange Lab Tests
    Ask your healthcare provider for serum ALP and related blood tests.

  5. Explore Treatment Options
    Discuss enzyme replacement therapy, nutrition, and lifestyle changes with your doctor.

When to Seek Immediate Medical Attention

Some symptoms can signal serious complications. Contact a healthcare professional right away if you experience:

  • Severe, sudden bone or joint pain
  • Signs of fracture (swelling, inability to bear weight)
  • Symptoms of low calcium (muscle cramps, numbness, tingling)
  • Difficulty breathing or chest pain

If you’re ever in doubt about the seriousness of your condition, speak to a doctor immediately.

Living Well with HPP Disease

While HPP can present challenges, many adults lead full, active lives with proper management. Key tips:

  • Stay informed about new treatments and research
  • Build a supportive care team (primary doctor, specialist, dietitian, physical therapist)
  • Connect with patient advocacy groups for resources and community
  • Prioritize bone-friendly habits: balanced diet, safe exercise, fall prevention

Above all, open communication with your healthcare team ensures you get timely interventions and support. Remember that early recognition and consistent care make a significant difference in bone health and quality of life.


If you notice any worrying signs or suspect HPP disease, speak to a doctor about your concerns. Prompt attention and tailored treatment can help you maintain stronger bones and better overall health.

(References)

  • * Inoue M. [Hypophosphatasia]. Nihon Rinsho. 2006 Jun 28;Suppl 2:104-7. PMID: 16817361.

  • * Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Dahir KM, Nunes ME. Hypophosphatasia. GeneReviews(®). 1993. PMID: 20301329.

  • * Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2:380-8. PMID: 23858621.

  • * Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Lewiecki EM. Osteoporosis: Clinical Evaluation. Endotext. 2000. PMID: 25905277.

  • * Whyte MP. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2016 Apr;12(4):233-46. doi: 10.1038/nrendo.2016.14. Epub 2016 Feb 19. PMID: 26893260.

  • * Riancho JA. Diagnostic Approach to Patients with Low Serum Alkaline Phosphatase. Calcif Tissue Int. 2023 Mar;112(3):289-296. doi: 10.1007/s00223-022-01039-y. Epub 2022 Nov 8. PMID: 36348061.

  • * Cianferotti L. Osteomalacia Is Not a Single Disease. Int J Mol Sci. 2022 Nov 28;23(23). doi: 10.3390/ijms232314896. Epub 2022 Nov 28. PMID: 36499221; PMCID: PMC9740398.

  • * Schini M, Vilaca T, Gossiel F, Salam S, Eastell R. Bone Turnover Markers: Basic Biology to Clinical Applications. Endocr Rev. 2023 May 8;44(3):417-473. doi: 10.1210/endrev/bnac031. PMID: 36510335; PMCID: PMC10166271.

  • * Rush E, Brandi ML, Khan A, Ali DS, Al-Alwani H, Almonaei K, Alsarraf F, Bacrot S, Dahir KM, Dandurand K, Deal C, Ferrari SL, Giusti F, Guyatt G, Hatcher E, Ing SW, Javaid MK, Khan S, Kocijan R, Lewiecki EM, Linglart A, M'Hiri I, Marini F, Nunes ME, Rockman-Greenberg C, Roux C, Seefried L, Starling SR, Ward L, Yao L, Brignardello-Petersen R, Simmons JH. Proposed diagnostic criteria for the diagnosis of hypophosphatasia in children and adolescents: results from the HPP International Working Group. Osteoporos Int. 2024 Jan;35(1):1-10. doi: 10.1007/s00198-023-06843-2. Epub 2023 Nov 20. PMID: 37982855; PMCID: PMC10786745.

  • * Magagnoli J, Knopf K, Hrushesky WJ, Carson KR, Bennett CL. Ferric Carboxymaltose (FCM)-Associated Hypophosphatemia (HPP): A Systematic Review. Am J Hematol. 2025 May;100(5):840-846. doi: 10.1002/ajh.27598. Epub 2025 Feb 11. PMID: 39935027; PMCID: PMC11966349.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.